Latest news:          EntreChem participates in the ERA-Co-Biotech project MISSION…          [ read more ]

News & Press Releases

EntreChem and Genoma España enter a collaborative agreement

January 28th, 2006 - Oviedo (Spain)

EntreChem has signed an agreement with Genoma España, and it has been incorporated to Genoma’s Technology Portfolio. The agreement supports the creation of the company as well as represents an infusion of resources to EntreChem to finance start-up activities.

Genoma’s Technology Portfolio is a specific, well endowed program, whose objectives are: i) take advantage of scientific research results, ii) strengthen the capabilities of Technology Transfer Offices in the Biotechnology area, iii) generate technology projects in Biotechonology (patents, spin-offs) with attractive potential to private investment and iv) search industrial for partners commited to the development of technology projects.

go back
About Genoma España: Genoma España is the Foundation for the Development of Genomic and Proteomic Research. It is a public Foundation, backed by the Spanish State through the Ministries of Health and Consumer Affairs and Education and Science. It reports to the Ministry of Education and Science, but its decision organs are strongly participated by the private sector. Its main activities are i) direct support of research in genomics and proteomics, ii) support the research groups, centers and networks in biotechnology, iii) develop institutional relationships with domestic and interantional bodies, iv) disseminate and raise society awareness and v) facilitate technology transfer and support the creation of biotecnology companies. For further information, please visit

> About EntreChem SL: EntreChem is a start-up company founded as a spin-off of the University of Oviedo in 2005 by Prof. Vicente Gotor, Prof. José A. Salas and Francisco Morís, Ph.D. The company focuses on novel products obtained by biocatalysis and combinatorial biosynthesis approaches, as well as development of processes involving enzymatic catalysis and genetic engineering of metabolic pathways. More information can be found at